Retrophin, Inc. (NASDAQ:RTRX)

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases. It sells Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; and Vecamyl for the treatment of hypertension. The company develops Syntocinon Nasal Spray, an oxytocin nasal spray product for aiding milk let-down, as well as for the treatment of schizophrenia and autism; and RE-034, a synthetic hormone analogue that is composed of the first 24 amino acids of the 39 amino acids contained in the naturally occurring adrenocorticotrophic hormone for the treatment of infantile spasms and nephrotic syndrome. It also develops RE-024, a novel small molecule for the treatment of pantothenate kinase associated neurodegeneration; Sparsentan, a dual acting receptor antagonist of angiotensin and endothelin receptors for the treatment of focal segmental glomerulosclerosis; and RE-001, a therapy for the treatment of duchenne muscular dystrophy. In addition, the company intends to obtain FDA approval of Chenodal for the treatment of cerebrotendinous xanthomatosis; and for the treatment of patients with biliary cirrhosis. Retrophin, Inc. is based in New York, New York.